清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

A comparative study of esketamine-dexmedetomidine and sufentanil-dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA): a randomized double-blind clinical trial

右美托咪定 医学 麻醉 舒芬太尼 镇静 氯胺酮 围手术期 可视模拟标度
作者
Zhonglan Lin,Shuxin Li,Yun Zhou,Xiuyuan Lu,Bin Yang,Zusheng Yu,Yuan Cheng,Jianliang Sun
出处
期刊:BMC Anesthesiology [BioMed Central]
卷期号:23 (1) 被引量:4
标识
DOI:10.1186/s12871-023-02266-y
摘要

Abstract Objective To observe and evaluate the effectiveness and safety of Esketamine or Sufentanil combined with Dexmedetomidine for sedation and analgesia in lung tumor percutaneous radiofrequency ablation (PRFA) to provide a clinical basis for the optimization of sedation and analgesia in lung tumor PRFA protocols outside the operating room. Methods In this trial, 44 patients aged 37 to 84 undergoing lung tumor PRFA were enrolled and assigned to Group E (n = 22, Esketamine 0.2 mg/kg) or Group S (n = 22,Sufentanil 0.1 μg/kg ). Dexmedetomidine was infused intravenously as a sedative in both groups. The modified observer’s assessment of alertness and sedation scale (MOAAS), physical movement pain scale, intraoperative vital signs, anesthesia recovery time, radiologist and patient satisfaction rates, incidence of respiratory depression, and incidence of postoperative nausea and vomiting were recorded. Results Although there was no significant difference in the physical movement pain scale, blood oxygen saturation or incidence of perioperative adverse events between the two groups during ablation, the MOAAS, mean arterial pressure (MAP) and heart rate (HR) were higher in Group E than in Group S. The anesthesia recovery time was shorter in Group E than in Group S, and radiologist satisfaction was better in Group E than in Group S, but there was no significant difference between the two groups in terms of patient satisfaction. Conclusion Esketamine or Sufentanil combined with Dexmedetomidine is safe for lung tumor PRFA. However, in elderly patients with multiple underlying diseases, low-dose Esketamine combined with Dexmedetomidine has fewer hemodynamic effects on patients, milder respiratory depression, shorter recovery time, and better radiologist satisfaction because of its better controllability of sedation depth. Trial registration Chinese Clinical Trial Registry (Registration number#ChiCTR ChiCTR21000500 21); Date of Registration: 16/08/2021
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
王翎力完成签到,获得积分10
6秒前
elisa828发布了新的文献求助10
26秒前
万能图书馆应助Ggap1采纳,获得10
35秒前
活力的珊完成签到 ,获得积分10
59秒前
YY完成签到,获得积分10
1分钟前
elisa828发布了新的文献求助10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
Owen应助科研通管家采纳,获得200
1分钟前
Ava应助青柏采纳,获得10
1分钟前
科研通AI2S应助sugarmei采纳,获得10
1分钟前
王洋洋完成签到 ,获得积分10
1分钟前
2分钟前
2分钟前
青柏发布了新的文献求助10
2分钟前
冬1完成签到 ,获得积分10
2分钟前
JackFan完成签到,获得积分10
2分钟前
2分钟前
游01完成签到 ,获得积分10
2分钟前
3分钟前
3分钟前
cappuccino完成签到 ,获得积分10
3分钟前
无限的以亦完成签到,获得积分10
3分钟前
Kevin完成签到,获得积分10
3分钟前
ChatGPT完成签到,获得积分10
4分钟前
zzhui完成签到,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
elisa828发布了新的文献求助10
5分钟前
adinaaaalala关注了科研通微信公众号
5分钟前
朴实以丹完成签到 ,获得积分10
5分钟前
情怀应助科研通管家采纳,获得10
5分钟前
Owen应助科研通管家采纳,获得10
5分钟前
cadcae完成签到,获得积分10
5分钟前
GYQ完成签到,获得积分20
5分钟前
光合作用完成签到,获得积分10
6分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968520
求助须知:如何正确求助?哪些是违规求助? 3513331
关于积分的说明 11167298
捐赠科研通 3248700
什么是DOI,文献DOI怎么找? 1794417
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664